Brentuximab vedotin in treating Chinese patients with lymphoma: A multicenter, real-world study.

Xudong ZhangHonghan QiaoXiaofei ChaiXue GaoRongjun MaYufu LiZunmin ZhuMing-Zhi Zhang

Published in: Cancer medicine (2023)

BV-based regimens could be a promising therapeutic option with remarkable effectiveness and moderate toxicity in treating Chinese lymphoma patients with CD30 expression.

Keyphrases

diffuse large b cell lymphoma
hodgkin lymphoma
poor prognosis
randomized controlled trial
systematic review
oxidative stress
lipopolysaccharide induced
cross sectional
clinical trial
binding protein